Profilo
Johannes Holzmeister currently works at Cardiorentis AG, as Chairman & Chief Executive Officer and DiNAQOR AG, as Chairman & Chief Executive Officer.
Posizioni attive di Johannes Holzmeister
| Società | Posizione | Inizio |
|---|---|---|
Cardiorentis AG
 Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Amministratore Delegato | - |
DiNAQOR AG
 DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Cardiorentis AG
Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Health Technology |
DiNAQOR AG
DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Health Technology |
- Borsa valori
- Insiders
- Johannes Holzmeister
